Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Acadia Healthcare to Participate in the Barclays 26th Annual Global Healthcare Conference: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare to Participate in the Barclays 26th Annual Global Healthcare Conference


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the Barclays 26th Annual Global Healthcare Conference, which is being held March 12 - 14, 2024, in

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO


Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 (INNOVATE-3)

Premier, Inc. to Participate in Barclays Global Healthcare Conference on March 12, 2024: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Participate in Barclays Global Healthcare Conference on March 12, 2024


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in a fireside chat at the Barclays

Acadia Healthcare to Participate in Raymond James 45th Annual Institutional Investors Conference: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare to Participate in Raymond James 45th Annual Institutional Investors Conference


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the Raymond James 45th Annual Institutional Investors Conference, which is being held March 3 - 6

Xencor to Present at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at Upcoming Investor Conferences


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for

Acadia Healthcare Reports Fourth Quarter 2023 Results: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Reports Fourth Quarter 2023 Results


Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2023.



Fourth Quarter Highlights

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update


Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023. Novocure is a global oncology company working to extend survival in some of the most

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it

PINC AI™ and Fortune Name the Nation’s 50 Top Cardiovascular Hospitals™: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
PINC AI™ and Fortune Name the Nation’s 50 Top Cardiovascular Hospitals™


PINC AI, the technology and services brand of Premier, Inc. (NASDAQ: PINC), today announced the nation’s 50 Top Cardiovascular Hospitals. The full list of recognized hospitals was published in an

Premier, Inc.’s PINC AI™ Applied Sciences and Datavant Collaborate to Enable Next-Generation Clinical Trials: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc.’s PINC AI™ Applied Sciences and Datavant Collaborate to Enable Next-Generation Clinical Trials


PINC AI™ Applied Sciences (PAS), a division of Premier, Inc. (NASDAQ: PINC), and Datavant, the company that protects, connects and delivers the world’s health data, announce the companies are

Acadia Healthcare Announces Date for Fourth Quarter and Year-End 2023 Earnings Release: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Announces Date for Fourth Quarter and Year-End 2023 Earnings Release


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its fourth quarter and year-end 2023 results on Tuesday, February 27, 2024, after the close of the market. Acadia

Premier, Inc. Reports Fiscal-Year 2024 Second-Quarter Results: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Reports Fiscal-Year 2024 Second-Quarter Results


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2024 second quarter ended December 31, 2023.



"Our

Premier, Inc. Completes Strategic Review Process: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Completes Strategic Review Process


Premier, Inc. (NASDAQ: PINC) (“Premier” or the “Company”), a leading technology-driven healthcare improvement company, today announced that the Company’s Board of Directors has concluded its

Premier, Inc. Declares Quarterly Cash Dividend: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Declares Quarterly Cash Dividend


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer


Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic

Premier, Inc. to Report Fiscal 2024 Second-Quarter Results and Host Conference Call on February 6, 2024: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2024 Second-Quarter Results and Host Conference Call on February 6, 2024


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2024 second quarter on Tuesday, February 6, 2024, at approximately 6:30 a.m. ET. The company will

Acadia Healthcare and Ascension Seton Form Joint Venture to Expand Behavioral Health Services in Austin: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare and Ascension Seton Form Joint Venture to Expand Behavioral Health Services in Austin


Ascension Seton and Acadia Healthcare announced today that the two organizations have formed a joint venture to expand access to behavioral healthcare in Austin, Texas, and surrounding communities

Acadia Healthcare Enters Into a Joint Venture Partnership With Ascension Seton to Expand Behavioral Health Services in Austin, Texas: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Enters Into a Joint Venture Partnership With Ascension Seton to Expand Behavioral Health Services in Austin, Texas


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture partnership with Ascension Seton, one of the leading, integrated healthcare systems in Austin

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma


Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio® (formerly

Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update


Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2023. Novocure is a global oncology company

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer


Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and

Premier, Inc. to Participate in J.P. Morgan Healthcare Conference on January 9, 2024: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Participate in J.P. Morgan Healthcare Conference on January 9, 2024


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in the J.P. Morgan Healthcare

Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that

Acadia Healthcare to Present at the 42nd Annual J.P. Morgan Healthcare Conference: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare to Present at the 42nd Annual J.P. Morgan Healthcare Conference


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, at The Westin St. Francis, San